While many Americans rely on generic drugs as an inexpensive way to treat common ailments, common essential medications can vary in quality from manufacturer to manufacturer and even batch to batch of, especially when a drug goes generic. The team at New Haven-based Valisure saw a market opportunity and developed techniques and technology to make sure that each batch of medicine they distribute has been tested for many of the most important properties, like dosage, dissolution and contaminants.
Our speaker at WHIPgroup’s Meetup on Tuesday, June 16, is David Light, CEO of Valisure. A repeat entrepreneur who’s worked for several successful biotech startups. David is a repeat entrepreneur who’s worked for several successful biotech startups. He will share his insights into the current world of healthcare and the opportunities presenting themselves to biotech leaders with the background and drive to get things done.
The SDNY recently granted a Motion to Dismiss in favor of WHIPgroup clinet, Koslow Technologies Corporation, securing a $18M Arbitration Award. Back in March, WHIPgroup client, Koslow Technologies Corporation (Koslow), was awarded a $18M Partial [Read More…]
Infogation Corporation filed a patent infringement lawsuit in EDTX against WHIPgroup client, TomTom International B.V. TomTom International B.V., a Netherlands corporation, was never served papers related to the lawsuit. However, service was attempted on TomTom [Read More…]
Koslow Technologies Corporation (Koslow) was sued in the SDNY in a 100-page complaint seeking over $1B on a contract claim related to gravity water filters which remove viruses. In addition to $1B, One World Filter [Read More…]